Side effects included nausea (39% of patients), diarrhea (25%) and vomiting (28%) [29] Overall, orfoglipron achieves comparable weight loss with other GLP1R agonists such as semaglutide and Rybelsus, but has a slightly better side effect profile and achieves weight loss in a shorter period of time
Here are the types of patients that may benefit most from each treatment: Before making a decision, practitioners should carefully explain the expected outcomes, side effect profiles , session counts, and downtime for each treatment
It is still in the clinical trial phase, with more studies going on right now to see how well it works, how safe it is, and what might happen with long-term use
However, the total number of interstitial cells from rhGH rat testes was not different from control on PND 24